Archive for the ‘General Interest’ category

Evidence Mounts That Outdoor Recess Time Can Reduce The Risk of Nearsightedness in Children

June 17th, 2013

Two new studies add to the growing evidence that spending time outdoors may help prevent or minimize nearsightedness in children. A study conducted in Taiwan, which is the first to use an educational policy as a public vision health intervention, finds that when children are required to spend recess time outdoors, their risk of nearsightedness is reduced. A separate study in Danish children is the first to show a direct correlation between seasonal fluctuations in daylight, eye growth and the rate of nearsightedness progression. The research was published in the May issue of Ophthalmology, the journal of the American Academy of Ophthalmology.

Nearsightedness in childhood is correctable, but is also linked to development of severe forms of this eye disorder in adulthood, which increases risks for potentially blinding diseases such as glaucoma and retinal detachment. Research on nearsightedness, also called myopia, is intensifying as the condition nears epidemic status in Asia and other regions, primarily in developed countries. In the United States nearsightedness has increased by more than 65 percent since 1970[1]. Though myopia is often inherited, researchers are now assessing environmental factors to help explain why myopia rates are rising so rapidly in some populations[2].

In one of the new studies, an elementary school in Taiwan required its 333 students to spend recess outdoors for a year from 2009-10 so that researchers could learn whether this would reduce myopia rates. A similar school nearby served as the control group and did not require outdoor recess. The children in the intervention school, many of whom had formerly spent recess indoors, now spent a total of 80 minutes per day outdoors.

Students at both schools received eye exams at the study outset and one year later. The results showed that significantly fewer children became nearsighted or shifted toward nearsightedness in the school that required outdoor recess, compared with the control school. The researchers recommend that elementary schools in Asia and other regions add frequent recess breaks and other outdoor activities to their daily schedules to help protect children’s eye development and vision.

Pei-Chang Wu, M.D., PhD.

“Because children spend a lot of time in school, a school-based intervention is a direct and practical way to tackle the increasing prevalence of myopia,” said the leader of the study, Pei-Chang Wu, M.D., PhD., of Kaohsiung Chang Gung Memorial Hospital in Kaohsiung, Taiwan.

A separate study on the impact of daylight exposure on eye development analyzed data collected in a 2005 clinical trial that included 235 Danish school children with myopia. The participants were divided into seven groups, each of which represented a different seasonal interval. Because daylight hours fluctuate markedly with the seasons in Denmark, from seven hours in winter to nearly 18 in summer, access to daylight was distinct for each group. Axial eye length – the distance from the front to the back of the eye – and vision were tested in each group of children at the beginning and end of their seasonal interval. Axial length is an important measurement because elongation of the eye indicates that the person’s myopia is worsening. In the children with access to the fewest hours of daylight, eye growth averaged 0.19 mm; in those with access to the most daylight, eye growth was just 0.12 mm.

“Our results indicate that exposure to daylight helps protect children from myopia,” said the leader of the study, Dongmei Cui, M.D., Ph.D., of Sun Yat -sen University, China. “This means that parents and others who manage children’s time should encourage them to spend time outdoors daily. When that’s impractical due to weather or other factors, use of daylight-spectrum indoor lights should be considered as a way to minimize myopia.”

About the American Academy of Ophthalmology
The American Academy of Ophthalmology–headquartered in San Francisco– is the world’s largest association of eye physicians and surgeons — Eye M.D.s — with nearly 32,000 members worldwide. Eye health care is provided by the three “O’s” – ophthalmologists, optometrists, and opticians. It is the ophthalmologist, or Eye M.D., who can treat it all: eye diseases, infections and injuries, and perform eye surgery. For more information, visit www.aao.org. The Academy’s EyeSmart® program educates the public about the importance of eye health and empowers them to preserve healthy vision. EyeSmart provides the most trusted and medically accurate information about eye diseases, conditions and injuries. OjosSanos™ is the Spanish-language version of the program. Visit www.geteyesmart.org or www.ojossanos.org to learn more.

About Ophthalmology
Ophthalmology, the official journal of the American Academy of Ophthalmology, publishes original, peer-reviewed reports on ophthalmic research, including basic science investigations, clinical studies, and translational science reviews. Topics include new diagnostic and treatment approaches, innovations in surgical technique, clinical trial results, economic and quality of life analyses, and implications of health care reform. Ophthalmology is one of the most respected journals in medicine, with the highest impact factor of the major journals serving ophthalmology.

[1] Increased Prevalence of Myopia in the United States between 1971-1972 and 1999-2004. Arch Ophthalmol 2009;127(12):1632-1639

[2] High heritability of myopia does not preclude rapid changes in prevalence. Clin Experiment Ophthalmol 2002;30:168 –72.


Bookmark and Share

Groundbreaking Corneal Transplant with Pre-loaded Donor Tissue Performed at Massachusetts Eye and Ear

June 14th, 2013

The first successful cornea transplant with donor endothelial tissue preloaded by an eye bank has been performed at Massachusetts Eye and Ear in Boston, Mass. Roberto Pineda II, M.D., Director of the Refractive Surgery Service at Mass. Eye and Ear, and Associate Professor of Ophthalmology at Harvard Medical School, recently performed the groundbreaking transplant.

Dr. Pineda performed the surgery utilizing donor endothelial tissue that was prepared and pre-loaded into EndoGlide™ (Angiotech Pharmaceuticals, Inc.) cartridges at the Lions Eye Institute for Transplant & Research (LEITR) in Tampa, FL. Massachusetts Eye and Ear cornea surgeon Kathryn Colby, M.D. has also performed surgeries with the pre-loaded tissue.

According to Dr. Pineda, using preloaded donor tissue may minimize potential damage to the endothelial cells and, thus, may lead to better outcomes for the patient.
The procedure – called Endothelial Keratoplasty – allows surgeons to preserve the majority of a recipient’s cornea while replacing the non-functioning or diseased portion of the cornea with a healthy donor tissue.

Roberto Pineda II, M.D.

“Reducing any variables that could interfere with a patient’s ability to successfully regain sight after surgery is significant,” said Dr. Pineda. “The ultimate goal is to improve the quality of life for our patients,” Dr. Pineda said.

A world-leading cornea expert and refractive surgeon at Mass. Eye and Ear, Dr. Pineda has collaborated with LEITR and Angiotech/Sharpoint for the last seven months to help develop the innovative procedure.

“I am pleased that – with Dr. Pineda leading these efforts – Mass. Eye and Ear is at the forefront of implementing an innovative technology that could greatly improve the quality of surgical outcomes for patients facing partial or complete vision loss,” said Joan W. Miller, M.D., FARVO, Chief and Chair of Ophthalmology at Mass. Eye and Ear and Harvard Medical School.

Last year, LEITR reported that eye banks are able to safely prepare and load corneal tissue into the EndoGlide™ cartridges. In a pre-clinical study presented at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, corneal buttons pre-loaded by LEITR sustained an average of 9.07% endothelial cell damage, compared to 36.2% endothelial cell damage in control group tissue that was loaded into the insertion system on site. The difference in endothelial damage between the preloaded and control buttons was statistically significant (P = 0.004).

About Massachusetts Eye and Ear
Massachusetts Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. Mass. Eye and Ear/Schepens is the world’s largest vision and hearing research center, developing new treatments and cures through discovery and innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report’s “Best Hospitals Survey” has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as top five in the nation. For more information about life-changing care and research, or to learn how you can help, please visit www.masseyeandear.org.

About the Lions Eye Institute for Transplant & Research
The Lions Eye Institute for Transplant & Research, Inc., (LEITR) is a nonprofit organization dedicated to the recovery, evaluation and distribution of eye tissue for transplantation, research and education. LEITR’s Eye Bank, located in Tampa, FL., is the only combined eye bank and ocular research center in the world. Since its inception, it has brought the “Gift of Sight” to more than 55,000 men, women and children worldwide. For more information, visit www.lionseyeinstitute.org. LEITR is a proud member of Vision Share, a highly organized network of the most innovative and successful eye banks.

www.masseyeandear.org

Bookmark and Share

Fish Oil Doesn’t Seem To Help Age-Related Macular Degeneration

June 13th, 2013

A large-scale National Eye Institute study has shown fish oil supplements containing omega-3 fatty acids do not alter the progression of age-related macular degeneration, says a national team of researchers including David M. Brown, M.D., an retina specialist at The Methodist Hospital who ran Houston’s part of the study.

Another key finding of the Age-Related Eye Disease Study 2, or AREDS 2, is that lutein and zeaxanthin may be safer than beta-carotene in reducing risk of disease progression.

A retina with age-related macular degeneration, or AMD, converting from the dry form of the disease (yellow mottling) to the wet form (red spots). Image by Eric Kegley.

“If you look at all the analysis performed in the AREDS 2 study, it looks like lutein taken with zeaxanthin is at least as effective and may be better than beta-carotene,” Brown said. “If you also consider that beta-carotene was associated with increased lung cancer rates in all former smokers, I no longer recommend any formulations containing beta-carotene.”

Researchers saw a modest decrease in the development of age-related macular degeneration (AMD) among those who took high amounts of zinc, but that result was not statistically significant.

“Millions of older Americans take nutritional supplements to protect their sight without clear guidance regarding benefit and risk,” said NEI director Paul A. Sieving, M.D., Ph.D. “This study clarifies the role of supplements in helping prevent advanced AMD, an incurable, common, and devastating disease that robs older people of their sight and independence.”

Like beta-carotene, lutein and zeaxanthin can be converted to vitamin A in humans and can collect at the retina, where they probably limit chemical damage caused by light. Lutein is found in foods like egg yolk and animal fat deposits. Zeaxanthin is found in some berries, corn, and paprika.

AREDS 2′s results agree with past studies that have shown an association between beta-carotene consumption and the development of lung cancer in current or former smokers. About half of AREDS 2 participants reported having been smokers at some point in their lives.

David M. Brown, M.D.

Macular degeneration is a disease in which retina damage causes a loss of visual acuity in the center of the eye, called the macula. AMD is a major cause of blindness in the elderly, and currently affects about 11 million Americans. National Eye Institute experts believe that number will double by 2050.

About 12 years ago, the National Eye Institute began funding studies to look at how diet and dietary supplements affect the progression of the disease. AREDS showed a 25 percent decreased risk of AMD when study participants took vitamin C, beta-carotene (a precursor to vitamin A), vitamin E, zinc, and copper (called the AREDS Formulation).

The five-year AREDS 2, which began in 2006, was a national study of more than 4,200 people. It suggests fish oil supplements probably do not need to be added to the formulation, and that lutein with zeaxanthin might replace beta-carotene in the AREDS Formulation, since lutein is not associated with increased risk for lung cancer.

“The first AREDS study showed us that vitamins really make a difference in decreasing the complications of AMD,” Brown said. “Now with the AREDS 2, we have solid data on what to recommend to our patients. Based on the AREDS 2 data, I now recommend that my patients no longer take beta-carotene but look for a vitamin with 10 mg Lutein, 2 mg zeaxanthin, 80mg zinc, 2mg copper, 500mg vitamin C, and 400 IU vitamin E.”

AREDS 2 was chaired by Frederick L. Ferris III, M.D., director of the Division of Epidemiology and Clinical Applications at NEI.

www.methodisthealth.com

Bookmark and Share

MYKITA and Cote&Ciel Create a New Collection of Eyewear Pouches

June 6th, 2013

Just in time for summer, MYKITA has partnered up with French accessories brand Côte&Ciel, known for their iconic designs for people on the move, to create a distinctive collection of protective eyewear pouches.

Slipped into a pocket or bag, frames will not only be easily accessible but also travelling in style, no matter if it’s to the beach, the forest or a picnic.

The pouches are made from Côte&Ciel’s signature diamond grip mesh neoprene. Durable and sleek they are a practical solution to keep your beloved frames protected and always at hand. The inverted zip and safety lip prevents scratching your eyewear. And, to make it even better – an integrated microfiber cleaning cloth allows you to keep your lenses smudge free while removing the inconvenience of looking for or even losing that rather invaluable piece of fabric.

www.mykita.com

Bookmark and Share

China’s Baidu Developing Digital Eyewear Similar To Google Glass

April 30th, 2013

Baidu Inc, China’s largest search engine, is developing prototype digital eyewear similar to Google Inc’s Google Glass that will leverage Baidu’s strengths in image search and facial recognition, a Baidu spokesman said.

Internally known as project “Baidu Eye”, the glasses are being tested internally and it is not clear whether the product will ever be commercialized, said Kaiser Kuo, Baidu’s spokesman.

Kuo said the device will be mounted on a headset with a small LCD screen and will allow users to make image and voice searches as well as conduct facial recognition matches.

“What you are doing with your camera, for example, taking a picture of a celebrity and then checking on our database to see if we have a facial image match, you could do the same thing with a wearable visual device,” Kuo said.

Baidu’s first foray in wearable technology will draw comparisons to Google’s Google Glass product, which is a piece of electronic eyewear that can live-stream images and audio and perform computing tasks. Earlier this year Google launched the Google Glass Explorer program, opening up the eyewear for early enthusiasts to test.

Kuo said comparisons to Google Glass were premature as Baidu has not decided whether or not to commercialize the product.

“We haven’t decided whether it is going to be released in any commercial form right now, but we experiment with every kind of technology that is related to search,” Kuo said. Kuo declined to comment on the other functions of the Baidu Eye or whether Baidu is working on other forms of wearable technology.

Wearable technology is the latest technology initiative with many firms, including Google and Apple Inc, set to roll out devices based on the belief that users will increasingly seek to stay connected without being tethered to a desktop, laptop or tablet computer.

Apple is experimenting with a device similar to a wristwatch that would operate on the same platform as the iPhone and would be made with curved glass, the New York Times reported in February.


Bookmark and Share

April Is National Sports Eye Safety Month Across America

April 8th, 2013

It’s estimated that 40,000 Americans receive eye injuries while participating in sports every year. This is a sobering statistic, especially considering that studies have shown that 90% of eye injuries could have been prevented simply by wearing protective eyewear. These are just some of the reasons why Wiley X, Inc. continues to support Sports Eye Safety Month, an annual effort each April to educate and inform the American public about the dangers of sports related eye injuries and the proper use of protective eyewear.

“The fact of the matter is, your eyes are at risk anytime you participate in sports — on the field, on the court or in the outdoors,” said Wiley X Co-Owner Myles Freeman, “Even sports not normally considered ‘dangerous’ — such as tennis, soccer or golf — can result in serious injury if protective eyewear isn’t worn. And outdoor activities like mountain biking, skateboarding and beach volleyball pose their own unique risks to eye health. The risks to one’s eyes may be varied, but the solution is the same — wear protective glasses to protect your precious gift of vision,” added Freeman.

Fortunately, sports enthusiasts today have a variety of premium quality eyewear options that deliver comfort, style and crystal clear vision along with serious vision protection. For example, Wiley X’s popular Climate Control™ series sunglasses feature a patented, removable soft foam Facial Cavity™ Seal that blocks out wind, dust and debris and provides a safe, climate-controlled environment for the eyes. The company’s sports-oriented Active Series features lightweight, comfortable frames with rubber nose and temple grips for a secure fit during high-action, high-sweat activities. And the majority of Wiley X eyewear styles are RX ready, providing sportsmen and women with an ideal, no-compromise solution on the field of play.

Whichever Wiley X style sports enthusiasts choose, they can play all-out knowing their eyes are protected from a wide range of hazards — from a blazing line-drive to a wicked forehand smash to a low-hanging branch. Wiley X sunglasses meet stringent ANSI-Z87.1 High Velocity and High Mass Impact Safety standards, providing wearers with OSHA-grade protection. Wiley X is the only premium sunglass brand with this level of protection in every pair of glasses it makes — a key reason why the company has been a leading provider of vision protection to U.S. military forces for more than 25 years.

For general information about Sports Eye Safety Month, visit the American Academy of Ophthalmology’s special website at www.geteyesmart.org. To learn more about Wiley X’s extensive line of premium protective eyewear for sports and all kinds of outdoor activities — visit Wiley X, Inc. at 7800 Patterson Pass Road, Livermore, CA 94550 • Telephone: (800) 776-7842 • Or visit online at www.wileyx.com


Bookmark and Share

John Varvatos Celebrates 10th Annual Stuart House Benefit at Los Angeles Boutique

April 5th, 2013

John Varvatos celebrated the 10th Annual Stuart House Benefit, presented by Chrysler, at his Los Angeles boutique. The March 10th event, hosted by Jennifer Garner and Ben Affleck, took over Melrose Avenue and Robertson at the heart of West Hollywood and raised more than $900,000 for Stuart House – UCLA’s internationally recognized model program serving sexually abused children.

The event’s emcee, Bill Belamy, hosted the live auction followed by a performance by Steven Tyler and Joe Perry of Aerosmith with special guest Slash. Among the guests to arrive in John Varvatos eyewear were Jeremy Piven, Joe Manganiello, Cindy Crawford and Rande Gerber, Alice Cooper, David Schwimmer, Ben Affleck and Jennifer Garner, Kevin Nealon, Vincent Piazza and more.

For more information about Stuart House and to learn how you can help please visit www.911rape.org.

About John Varvatos
Launched in 2000 with a collection of tailored clothing and sportswear, John Varvatos now represents an entire men’s lifestyle that includes footwear, bags, belts, eyewear, limited edition watches, men’s fragrances, as well as the younger, edgier John Varvatos USA Collection and Converse by John Varvatos. The designer has been recognized three times by the CFDA with an American Fashion Award for New Menswear Designer (June 2000) and Menswear Designer of the Year (June 2001 and June 2005) and was honored as GQ’s “Designer of the Year” in 2007. The collection is distributed in freestanding John Varvatos boutiques across the US and on johnvarvatos.com, as well as in better department stores throughout the world.

About REM Eyewear
Serving more than 80 nations on six continents, REM Eyewear is a leading designer and marketer of eyewear worldwide, with headquarters in Los Angeles, Sydney, Hong Kong, and the UK. REM’s portfolio of brands includes Converse, Jones New York, John Varvatos, Tumi, Lucky Brand, Lucky Kid, Cosmopolitan, Indie, Lipstick, and Surface. Family owned-and-operated for more than fifty years, the company is headed by industry veterans Mike Hundert (CEO) and Donna Gindy (COO), Steve Horowitz (President), and Nicolas Roseillier (Creative Director). www.remeyewear.com


Bookmark and Share

FDA Approves Bionic Eye To Help Against Rare Vision Disorder

April 2nd, 2013

Grid of electrons directly implanted on the retina.

An implanted, sight-enhancing device some are calling a “bionic eye” is the first to gain approval for use in the United States.

According to the U.S. Food and Drug Administration, the new Argus II Retinal Prosthesis System can help patients with a genetic eye disease called retinitis pigmentosa regain some sense of vision. About 100,000 Americans are believed to be affected by the illness, which causes a gradual deterioration of the eyes’ photoreceptor cells.

The new device uses a tiny video camera attached to eyeglasses that transmits images to a sheet of electrode sensors that have been sewn into the patient’s eye. These sensors then transmit those signals to the brain via the optic nerve. The device helps replace the damaged cells of the retina and helps patients see images or detect movement.

Dr. Mark Fromer

“It’s a start, it’s a beginning,” said Dr. Mark Fromer, an ophthalmologist at Lenox Hill Hospital in New York City. “It’s going to be exciting for people who get this device who are currently just seeing light or dark, [they] will see shapes and that will be life-altering for them.”

An FDA official was similarly enthused.

“For many of the approximately 1,300 individuals who will develop the disease this year, this technology may change their lives,” Dr. William Maisel, deputy director for science and chief scientist at FDA’s Center for Devices and Radiological Health, said in an agency blog post. “It’s the difference between night and day,” he added.

Maisel’s post also included testimony from people who had tested the device and spoke in favor of its approval at a recent FDA hearing:

“The biggest thing to me was being able to see the crosswalk lines on the street so I can safely cross streets in Manhattan,” one user said.

“The most exciting day to me was October 27th, in 2009,” another testified. “It was the first time I was able to see letters on the monitor screen [during a test of visual perception]. I had not seen letters since 1994, so that was huge.”

Headset for the Argus II retinal implant device.

A third person said he had a 17-year-old son, “and I don’t mind telling you how much — I mean, how happy that made me, not only to see the silhouette of my son, but to hear that voice coming and saying, ‘Yeah, it’s me, Dad. I’m here and I love you.’”

People with retinitis pigmentosa suffer damage to the light-sensitive cells of the retina. As these cells slowly degenerate, patients lose side vision and night vision and later on, central vision. The disease can cause blindness.

The FDA’s approval is a limited one, labeled a “humanitarian use device” approval, meaning the Argus II can be used only for fewer than 4,000 patients per year.

The FDA is currently restricting approval to people aged 25 years and older who have severe retinitis pigmentosa and can see light but not identify its source. Eligible patients also include those who cannot see light, but who have some retinal function and a history of being able to see forms.

Dr. Robert Greenberg

In addition, patients must be willing and able to get the recommended follow-up, device fitting and visual rehabilitation, the agency said.

Dr. Robert Greenberg, president and CEO of Second Sight Medical Products Inc., the maker of the device, said that “patients with retinitis pigmentosa in the United States for the first time ever will [now] have a treatment option.”

Greenberg said the device does not restore full vision, but does give patients what he calls “low vision,” meaning it lets them perform visual tasks that they couldn’t otherwise do.

This is only the first step, Greenberg added. “One of the great things about the Argus II system is that it is a software-driven system,” he said, and “we expect to be producing software upgrades for all the implanted patients.”

Current lab work suggests those upgrades will include color vision and sharper images, he said. “We are also working on more advanced implants,” Greenberg said.

The device is not cheap — in Europe, where the device has been approved for use for several years, it typically costs about $100,000, with an additional $16,000 for the operation. The company hasn’t set a U.S. price yet, but Greenberg say it is going to exceed $100,000.

Insurance typically covers the cost in several European countries, and the company has started a process to get it covered in the United States, Greenberg said.

To gain FDA approval, the system had to go through a clinical trial to see if the device was both safe and effective. The results showed that most participants could perform basic activities better with the device than without.

Activities tested included locating and touching a square on a white field; detecting the direction of a motion; recognizing large letters, words or sentences; detecting street curbs; walking on a sidewalk without stepping off; and matching black, gray and white socks, according to the FDA.

Among the 30 people in the study, 19 had no adverse events related to the implant surgery.

Eleven patients, however, did experience serious problems. These included erosion of the layer covering the eyeball called the conjunctiva, opening of the wound left by the operation, retinal detachment, inflammation and low pressure in their eyeball, the agency noted.


Bookmark and Share

Vogue Eyewear Celebrates New Communication Campaign Starring Eva Mendes

March 20th, 2013

On March 13th, Beverly Hills was the setting for the most exclusive party in town: the launch of the new Spring/Summer 2013 communication campaign with internationally-acclaimed actress, Eva Mendes. The global launch took place at the Simon House, a stunning California estate with sweeping views of Los Angeles, providing the perfect backdrop for a glamorous evening.

The invite-only party was hosted by the brands newest ambassador, the breathtaking Eva Mendes who was the undisputed star of the evening as she celebrated the exciting new partnership with Vogue Eyewear. Inspired by the colorful theme of the campaign, the regal mansion was transformed into Eva’s personal manor. Throughout the night, guests enjoyed exclusive styling experiences and VIP treatments while they previewed the latest collection of Vogue Eyewear.

The evening featured the sounds of stylish New Yorker Hannah Bronfman. Over the past few years, Hannah has quickly become one of the hottest young DJ’s on the fashion scene, bringing her love of music and style together in her work.

Mariavittoria Di Stasi, Vogue Eyewear Brand Director, “The launch of the new Vogue Eyewear communication campaign with Eva Mendes was the most exclusive and glamorous launch event in Los Angeles. The attendance of our ambassador definitely contributed in making the night unforgettable.”

The Spring/Summer 2013 communication campaign starring Eva Mendes features six brightly colored images as seen through the lens of renowned fashion photographer, Mario Testino. Playing on the vibrant shades of the eyewear collection and her electric personality, the campaign embraces the divine charm of the talented actress. As the new testimonial for Vogue Eyewear, Eva follows in footsteps of fashion icons, Kate Moss and Gisele Bündchen.

Eva Mendes recently appeared in the highly-praised fantasy, Holy Motors and co-stars with Ryan Gosling and Bradley Cooper in Derek Cianfrance’s upcoming The Place Beyond the Pines.

vogue-eyewear.com

Bookmark and Share

Research Poised To Lead To Major Advances In Cataract Treatment

March 20th, 2013

Professor Barbara Pierscionek

Research carried out by Professor Barbara Pierscionek and a team of fellow vision experts suggests that the way proteins are distributed in the lens of the eye may cause its gradient to be stepped rather than smooth as previously thought. The finding could give a new insight into the way the eye grows and lead to major improvements in synthetic lenses used in surgery to treat patients who have developed cataracts.

Artificial replacements did not currently match the quality of real ones, Professor Pierscionek said. “However this research could help give patients better vision if manufacturers use it to develop an improved lens able to change focus,” she explained.

Professor Pierscionek, the Associate Dean of Research and Enterprise at Kingston’s Faculty of Science, Engineering and Computing, has devoted two decades to researching the eye’s lens. Her work has explored its biochemical, optical and mechanical properties. Since the lens is one of the few organs in the body that does not replenish itself, it is a model for ageing. “The lens is the key to a lot of things – we just haven’t unlocked its full potential yet. It has the capacity to tell us what has happened to a person throughout their life and their disease state,” Professor Pierscionek said.

Cataracts can occur at any age, but often develop as people get older. In the United Kingdom, an estimated one in three people over the age of 65 is affected. Smoking and UV radiation are thought to be causes and they can also occur in people with diseases such as diabetes. The condition may gradually make vision more blurred and make it difficult to see in poor light. Treatment usually involves replacing the affected lens with an artificial one.

Professor Pierscionek carried out much of her most recent research at Japan’s Spring-8 synchrotron facility – home of the world’s largest third generation synchrotron. It accelerates electrons close to the speed of light to generate X-rays and other beams. The electrons are injected into a storage ring 1.4km in diameter, with the resultant X-rays fed into experimental stations dotted around the site. “These X-rays can penetrate parts of the body and soft tissue better than other forms of radiation,” Professor Pierscionek said. “This allows engineers and scientists to look deeply into anything from metal to bacteria.” When taking measurements it was important to keep the sample as close as possible to its natural state, Professor Pierscionek said. “The synchrotron is so sophisticated that it allows us to measure the lenses while they are still in the eyeball.”

Some of the research has been conducted in collaboration with scientists from the Spring-8 facility and Cardiff University. It is being funded by eye research charity Fight for Sight as well as grants from Spring-8, which has provided use of the synchrotron.

Further analysis is now being carried out in laboratories at Kingston University. Professor Pierscionek and her team are working with Dr Mehdi Bahram, a researcher funded by Fight for Sight, using ray tracing and mathematical modelling. The work involves projecting lasers of different colours through different parts of the lens to trace their paths. The information will then be used to help develop lenses with improved optical quality.

www.kingston.ac.uk

Bookmark and Share